Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
CA 2483451 C · Owner: Munn, David · Inventors: Munn, David; Mellor, Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance APCs having , high levels of IDO may be used to increase tolerance in the immune system as , for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO and expressing or loaded with at , least one antigen from a donor tissue may be used to increase tolerance of the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 12, 2002 and granted July 29, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 12, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 12, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.